Xref: utzoo soc.motss:45326 sci.med.aids:2613 Path: utzoo!utgpu!news-server.csri.toronto.edu!cs.utexas.edu!usc!ucla-cs!news From: sys0002@dircon.co.uk (Julian Hayward) Newsgroups: soc.motss,sci.med.aids Subject: Re: Something from GayNet re:HIV vaccine. Message-ID: <1991Feb12.142731.29249@cs.ucla.edu> Date: 12 Feb 91 14:35:58 GMT References: <1991Feb8.113638.4686@cs.ucla.edu> <1991Feb11.005044.7108@cs.ucla.edu> Sender: news@cs.ucla.edu (Shemp News Account) Organization: The Direct Connection, UK Lines: 34 Approved: phil@wubios.wustl.edu Note: non-commercial reproduction. Nntp-Posting-Host: squid.cs.ucla.edu Archive-Number: 3008 bywater!arnor!dgreen@uunet.UU.NET replies to: >|> > HIV vaccin (VAXSYN) is also under trial in Montreal. Phase I study >|> > was started last may. A Phase II study (placebo) started a few weeks ago. >... I was part of a group of >HIV- guinea pigs for it. No adverse effects, except for the typical >vaccine thing: a sore arm. Oh yeah, and a minor sociological >adverse effect: I produce misleadingly positive HIV antibody tests now. >Of course, this is not a problem for HIV infected individuals. >Regards, >____ >\ /Dan Greening IBM T.J.Watson Research Center NY (914) 784-7861 > \/ dgreen@ibm.com Yorktown Heights, NY 10598-0704 CA (213) 825-2266 Dan, Out of interest, how can they tell if the treatment is successful when it causes HIV- individuals like yourself to show HIV+? Is there a further test which can identify the difference from real HIV infected cells? I'd imagine you'd have a difficult time explaining this to an insurance company, perhaps they are more intelligent in the US/Canada. Julian -- ----------------------------------------------------------------- ()_() JULES | sys0002@dircon.co.uk (_) a.k.a. Julian Hayward | ----------------------------------------------------------------- -- ----------------------------------------------------------------- ()_() JULES | sys0002@dircon.co.uk (_) a.k.a. Julian Hayward | -----------------------------------------------------------------